These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 26450707)

  • 1. Topical treatment of basal cell carcinoma with the immune response modifier imiquimod.
    Papakostas D; Stockfleth E
    Future Oncol; 2015 Nov; 11(22):2985-90. PubMed ID: 26450707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imiquimod and lymphatic field clearance: a new hypothesis based on a remote immune action on skin cancer.
    Akkilic-Materna M; Massone C; Komericki P
    Acta Derm Venereol; 2011 Jun; 91(4):432-5. PubMed ID: 21547348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
    Tillman DK; Carroll MT
    Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
    Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
    Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imiquimod - Its role in the treatment of cutaneous malignancies.
    Bubna AK
    Indian J Pharmacol; 2015; 47(4):354-9. PubMed ID: 26288465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New perspective in immunotherapy: local imiquimod treatment].
    Kemény L; Nagy N
    Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
    Love WE; Bernhard JD; Bordeaux JS
    Arch Dermatol; 2009 Dec; 145(12):1431-8. PubMed ID: 20026854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond a decade of 5% imiquimod topical therapy.
    A Gaspari A; Tyring SK; Rosen T
    J Drugs Dermatol; 2009 May; 8(5):467-74. PubMed ID: 19537370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
    Vidal D; Matías-Guiu X; Alomar A
    Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ophthalmic side-effects of imiquimod therapy in the management of periocular skin lesions.
    Cannon PS; O'Donnell B; Huilgol SC; Selva D
    Br J Ophthalmol; 2011 Dec; 95(12):1682-5. PubMed ID: 20702431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions.
    Wagstaff AJ; Perry CM
    Drugs; 2007; 67(15):2187-210. PubMed ID: 17927284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of imiquimod in skin cancer treatment.
    Urosevic M; Dummer R
    Am J Clin Dermatol; 2004; 5(6):453-8. PubMed ID: 15663342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma.
    Sapijaszko MJ
    Skin Therapy Lett; 2005; 10(6):2-5. PubMed ID: 16292452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Photodynamic therapy vs imiquimod].
    Serra-Guillén C; Nagore E; Guillén C
    Actas Dermosifiliogr; 2012; 103(6):488-501. PubMed ID: 22178262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical application of imiquimod for the treatment of high-risk facial basal cell carcinoma in Gorlin syndrome.
    Vereecken P; Monsieur E; Petein M; Heenen M
    J Dermatolog Treat; 2004 Apr; 15(2):120-1. PubMed ID: 15204165
    [No Abstract]   [Full Text] [Related]  

  • 16. Imiquimod 5 percent cream and the treatment of cutaneous malignancy.
    Navi D; Huntley A
    Dermatol Online J; 2004 Jul; 10(1):4. PubMed ID: 15347486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imiquimod induces sustained remission of actinic damage: a case report spanning one decade of observation.
    Knackstedt TJ; Quitadamo M
    Cutis; 2015 Feb; 95(2):E20-3. PubMed ID: 25750973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.
    Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Tebbs V; Owens M; Stampone P
    Eur J Dermatol; 2005; 15(5):374-81. PubMed ID: 16172048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
    Huber A; Huber JD; Skinner RB; Kuwahara RT; Haque R; Amonette RA
    Dermatol Surg; 2004 Mar; 30(3):429-30. PubMed ID: 15008876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma.
    Torres A; Niemeyer A; Berkes B; Marra D; Schanbacher C; González S; Owens M; Morgan B
    Dermatol Surg; 2004 Dec; 30(12 Pt 1):1462-9. PubMed ID: 15606733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.